Source: http://www.asmscience.org/content/book/10.1128/9781555815974.ch32
Timestamp: 2019-04-23 20:10:45+00:00

Document:
HIV replication cycle. (A) Overview. (B) Reverse transcription. The retroviral genome contained in virions consists of RNA. Its characteristic features include terminal repeats (R), U5 (5′ untranslated), U3 (3′ untranslated), 3′ polyadenylation, a binding site for a tRNA which serves as the primer for reverse transcription, and the encapsidation signal Ψ. During reverse transcription, the viral RNA is reverse transcribed into double-stranded DNA, and terminal sequences are partially duplicated in a way that leads to an LTR composed of U3-R-U5. (C) Unintegrated circular DNA is a short-lived by-product of provirus integration; its presence in a cell sample indicates actively replicating virus. (D) Genomic organization of HIV-1 and HIV-2. The hatched boxes denote ORFs for proteins which are contained in particles. Drawing modified from Schüpbach, 2003b.
Origin of HIV-1 and HIV-2. (A) Phylogenetic tree of primate lentiviruses, derived from Pol protein sequences. Numbers 1 to 5 indicate the five major lineages. HIV-1/U455 is a group M, subtype A isolate. ELI is of group M, subtype D, and LAI is of group M, subtype B. ANT70 and MVP5180 represent group O, and YBF30 is group N. ROD and EHO represent different subtypes of HIV-2. SIVcpzGAB1, SIVcpzUS, and SIVcpzANT are chimpanzee (cpz) isolates. mnd, mandrill; agm, African green monkey; syk, Sykes’ monkey; sm, sooty mangabey. The bar at the bottom denotes genomic diversity. (B) Phylogenetic tree showing the relationship of HIV-1 groups M, N, and O to chimpanzee and gorilla (gor) lentiviruses, respectively. Combined and modified from Sharp et al., 1994, Gao et al., 1999, and Van Heuverswyn et al., 2006.
Translational products of HIV-1 and particle composition. (A) Translation. The open boxes in the genome representation at the top denote ORFs of the accessory proteins Tat, Rev, Nef, Vif, Vpr, and Vpu, which are translated into proteins of final size. The hatched boxes denote ORFs translated into precursor proteins. The products of the gag, pol, and env genes are synthesized as polyprotein precursors. The principal Gag precursor, Pr55Gag, is cleaved by the viral protease (PR or p10) into the matrix (MA) protein p17, the capsid (CA) protein p24, and a C-terminal protein p15, which is subsequently cleaved into p7 and the nucleocapsid (NC) protein p9. Cleavage of Pr160Gag-Pol, which is produced by ribosomal frameshifting at the gag-pol junction, yields PR, RT, and IN. All three enzymes remain dimerized after cleavage. RT first forms a homodimer, p66-p66, which is subsequently modified into the heterodimer, p66-p51. The Env precursor gp160 is glycosylated in the Golgi system, oligomerizes into dimers and trimers, and is cleaved by a cellular protease into the SU protein gp120 and the smaller TM protein gp41. The small arrows indicate protease cleavage sites. (B) Localization of viral proteins in mature virions.
Propagation of HIV from the mucosal entry port to the lymphatics and the bloodstream. FDC, follicular DC.
Virologic and immunologic parameters in the typical course of HIV infection.
Kit design and test performance of HIV screening tests. Synopsis of the most frequently used test formats, their principles, the meaning of positive results, and performance in two typical problem situations. Ag, antigen; Ab, antibody; hu, human.
Example of a false-positive HIV-1 WB interpretation according to ASTPHLD-CDC or Consortium for Retrovirus Serology Standardization guidelines. Lanes: a, weakly positive control; b, sample from a healthy individual exhibiting weak reaction with gp160, gp120 (very weak), and p24 (this sample was taken 3.5 months after an initial sample with the same pattern [data not shown]); c, sample from the same individual taken 1 month after the initial sample. p24 antigen with signal amplification-boosted ELISA was negative in all three plasma samples. PCR for viral DNA was negative in PBMC from the samples in lanes b and c, and RNA was negative in the sample in lane b. Culture with PBMC depleted of CD8 T cells from the sample in lane b was negative for p24 antigen and RT by the PERT assay; this test was also negative with the samples in lanes b and c.
Algorithms for diagnosis of HIV infection in adults. The darker shading represents algorithms of U.S. guidelines; the lighter shading illustrates possible alternatives. Reprinted from Schüpbach, 2003b, with permission.
Phylogenetic relationships of PTLV based on polymerase (pol; 662 bp). Sequences isolated from humans in the study by Wolfe et al. (2005) are shown in boxes. Support for the branching order is based on 1,000 bootstrap replicates; only values of 60% or more are shown. Branch lengths are proportional to the evolutionary distance (scale bar) between the taxa. Taxa abbreviations are: Ppn, Pan paniscus (bonobo); Mto, Macaca tonkeana (Celebes macaque); Ppa, Papio papio (Guinea baboon); Cto, Cercocebus torquatus (red-capped mangabey); Tge, Theropitecus gelada (gelada baboon); Pha, Papio hamadryas (sacred baboon). Reprinted from Wolfe et al., 2005, with permission.
HTLV-1 ORFs and transcription map. A scheme of the HTLV-1 genome, alternatively spliced mRNAs, and putative proteins encoded by each mRNA is shown. ORFs are indicated by boxes. Nucleotide numbering starts from the first nucleotide in the mRNA. Reproduced from Nicot et al., 2005, with permission.
Feedback regulation of HTLV-1 gene expression by Tax and Rex. Spontaneous viral expression of Tax from doubly spliced viral transcript. (1) Tax further activates subsequent viral transcription; (2) Rex encoded by the same mRNA as Tax suppresses splicing of viral RNA. (3) Thus, there is accumulation of unspliced mRNAs which express Gag, Pol, and Env proteins on the one side but downregulation of Tax/Rex expression and shutoff of transcription on the other side. Reprinted from Yoshida, 2005, with permission.
Morphology of ATLL cells. Note the typical nuclear indentations (flower cells). Reprinted with permission from Feller and Diebold, 2004.
Natural course from HTLV-1 infection to onset of ATLL. HTLV-1 is transmitted in a cell-to-cell fashion. After infection, HTLV-1 promotes clonal proliferation of infected cells by pleio-tropic actions of Tax and other viral proteins. Proliferation of HTLV-1-infected cells is controlled by cytotoxic T cells in vivo. After a long latent period, ATLL develops in about 5% of asymptomatic carriers. In ATLL, the expression of Tax is inactivated by several mechanisms, suggesting that Tax is no longer necessary in the ATLL stage. Alternatively, alterations and errors in the host genome accumulate progressively during the latent period, finally leading to onset of ATLL. Reprinted from Taylor and Matsuoka, 2005, with permission.
Epidemiologic map of HTLV-1. Countries with a prevalence between 1 and 5% in some populations are shown darkly shaded. Countries with a prevalence of less than 1% in some groups, due mainly to immigration from areas of endemicity, are shown lightly shaded. Note that areas of HTLV-1 endemicity do not correspond exactly to the country boundaries shown in the map. For example, HTLV-1 in Brazil, Japan, and Iran is limited to distinct areas within each country. Modified from Proietti et al., 2005, with permission.
1. Abe, A.,, A. Ishizu,, K. Fugo,, H. Ikeda, and, T. Yoshiki. 2006. Articular tissues expressing the env-pX transgene are required for generation of arthritogenic T cells in human T cell leukemia virus type I transgenic rats. Clin. Exp. Rheumatol. 24: 313– 316.
2. Abe, M.,, F. Umehara,, R. Kubota,, T. Moritoyo,, S. Izumo, and, M. Osame. 1999. Activation of macrophages/microglia with the calcium-binding proteins MRP14 and MRP8 is related to the lesional activities in the spinal cord of HTLV-I associated myelopathy. J. Neurol. 246: 358– 364.
3. Achachi, A.,, A. Florins,, N. Gillet,, C. Debacq,, P. Urbain,, G. M. Foutsop,, F. Vandermeers,, A. Jasik,, M. Reichert,, P. Kerkhofs,, L. Lagneaux,, A. Burny,, R. Kettmann, and, L. Willems. 2005. Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo. Proc. Natl. Acad. Sci. USA 102: 10309– 10314.
4. Albrecht, B.,, and M. D. Lairmore. 2002. Critical role of human T-lymphotropic virus type 1 accessory proteins in viral replication and pathogenesis. Microbiol. Mol. Biol. Rev. 66: 396– 406.
5. Ando, Y.,, Y. Ekuni,, Y. Matsumoto,, S. Nakano,, K. Saito,, K. Kakimoto,, T. Tanigawa,, M. Kawa, and, T. Toyama. 2004. Long-term serological outcome of infants who received frozen-thawed milk from human T-lymphotropic virus type-I positive mothers. J. Obstet. Gynaecol. Res. 30: 436– 438.
6. Anonymous. 1990. Acquired immunodeficiency syndrome (AIDS). Proposed WHO criteria for interpreting results from Western blot assays for HIV-1, HIV-2, and HTLV-I/HTLV-II. Wkly. Epidemiol. Rec. 65: 281– 283.
7. Anonymous. 1991. Biosafety Guidelines for Diagnostic and Research Laboratories Working with HIV, vol. 9. World Health Organization, Geneva, Switzerland.
8. Araujo, A. Q.,, and M. T. Silva. 2006. The HTLV-1 neurological complex. Lancet Neurol. 5: 1068– 1076.
9. Autran, B.,, G. Carcelain,, T. S. Li,, C. Blanc,, D. Mathez,, R. Tubiana,, C. Katlama,, P. Debre, and, J. Leibowitch. 1997. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277: 112– 116.
10. Baba, M. 2006. Recent status of HIV-1 gene expression inhibitors. Antivir. Res. 71: 301– 306.
11. Balvay, L.,, M. Lopez Lastra,, B. Sargueil,, J. L. Darlix, and, T. Ohlmann. 2007. Translational control of retroviruses. Nat. Rev. Microbiol. 5: 128– 140.
12. Bangham, C. R. 2003a. Human T-lymphotropic virus type 1 (HTLV-1): persistence and immune control. Int. J. Hematol. 78: 297– 303.
13. Bangham, C. R. 2003b. The immune control and cell-to-cell spread of human T-lymphotropic virus type 1. J. Gen. Virol. 84: 3177– 3189.
14. Bangham, C. R.,, and M. Osame. 2005. Cellular immune response to HTLV-1. Oncogene 24: 6035– 6046.
15. Barnhart, H. X.,, M. B. Caldwell,, P. Thomas,, L. Mascola,, I. Ortiz,, H. W. Hsu,, J. Schulte,, R. Parrott,, Y. Maldonado, and, R. Byers. 1996. Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project. Pediatrics 97: 710– 716.
16. Barre-Sinoussi, F.,, J. C. Chermann,, F. Rey,, M. T. Nugeyre,, S. Chamaret,, J. Gruest,, C. Dauguet,, C. Axler-Blin,, F. Vezinet-Brun,, C. Rouzioux,, W. Rozenbaum, and, L. Montagnier. 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220: 868– 871.
17. Bartholomew, C.,, F. Cleghorn,, W. Charles,, P. Ratan,, L. Roberts,, K. Maharaj,, N. Jankey,, H. Daisley,, B. Hanchard, and, W. Blattner. 1986. HTLV-I and tropical spastic paraparesis. Lancet ii: 99– 100.
18. Baxter, J. D.,, D. L. Mayers,, D. N. Wentworth,, J. D. Neaton,, M. L. Hoover,, M. A. Winters,, S. B. Mannheimer,, M. A. Thompson,, D. I. Abrams,, B. J. Brizz,, J. P. Ioannidis, and, T. C. Merigan. 2000. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 14: F83– F93.
19. Bazarbachi, A.,, V. Soriano,, R. Pawson,, A. Vallejo,, T. Moudgil,, E. Matutes,, J. Peries,, A. Molina,, H. de The,, T. F. Schulz,, D. Catovsky, and, P. S. Gill. 1997. Mycosis fungoides and Sezary syndrome are not associated with HTLV-I infection: an international study. Br. J. Haematol. 98: 927– 933.
20. Berger, E. A.,, R. W. Doms,, E. M. Fenyo,, B. T. M. Korber,, D. R. Littman,, J. P. Moore,, Q. J. Sattentau,, H. Schuitemaker,, J. Sodroski, and, R. A. Weiss. 1998. A new classification for HIV-1. Nature 391: 240.
21. Biberfeld, P.,, K. J. Chayt,, L. M. Marselle,, G. Biberfeld,, R. C. Gallo, and, M. E. Harper. 1986. HTLV-III expression in infected lymph nodes and relevance to pathogenesis of lymphadenopathy. Am. J. Pathol. 125: 436– 442.
22. Bittencourt, A. L.,, J. Primo, and, M. F. de Oliveira. 2006. Manifestations of the human T-cell lymphotropic virus type I infection in childhood and adolescence. J. Pediatr. (Rio de Janeiro) 82: 411– 420.
23. Bleul, C. C.,, M. Farzan,, H. Choe,, C. Parolin,, I. Clark-Lewis,, J. Sodroski, and, T. A. Springer. 1996. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382: 829– 833.
24. Bock, P. J.,, and D. M. Markovitz. 2001. Infection with HIV-2. AIDS 15 (Suppl. 5) : S35– S45.
25. Bogh, M.,, R. Machuca,, J. Gerstoft,, C. Pedersen,, N. Obel,, B. Kvinesdal,, H. Nielsen, and, C. Nielsen. 2001. Subtype-specific problems with qualitative Amplicor HIV-1 DNA PCR test. J. Clin. Virol. 20: 149– 153.
26. Boni, J. 1996. PCR detection of HIV. Methods Mol. Biol. 50: 93– 107.
27. Boni, J.,, L. R. Bisset,, J. J. Burckhardt,, H. I. Joller-Jemelka,, P. Burgisser,, L. Perrin,, M. Gorgievski,, P. Erb,, W. Fierz,, J. C. Piffaretti, and, J. Schupbach. 2004a. Prevalence of human T-cell leukemia virus types I and II in Switzerland. J. Med. Virol. 72: 328– 337.
28. Boni, J.,, M. Opravil,, Z. Tomasik,, M. Rothen,, K. Bisset,, P. Grob,, R. Lüthy, and, J. Schupbach. 1997. Simple monitoring of antiretroviral therapy with a signal-amplification-boosted HIV-1 P24 antigen assay with heat-denatured plasma. AIDS 11: F47– F52.
29. Böni, J.,, H. Pyra,, M. Gebhardt,, L. Perrin,, P. Bürgisser,, L. Matter,, W. Fierz,, P. Erb,, J. C. Piffaretti,, E. Minder,, P. Grob,, J. J. Burckhardt,, M. Zwahlen,, J. Huder, and, J. Schüpbach. 1999. High frequency of non-B subtypes in newly diagnosed HIV-1 infections in Switzerland. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 22: 174– 179.
30. Boni, J.,, H. Pyra, and, J. Schupbach. 1996a. Sensitive detection and quantification of particle-associated reverse transcriptase in plasma of HIV-1-infected individuals by the product-enhanced reverse transcriptase (PERT) assay. J. Med. Virol. 49: 23– 28.
31. Boni, J.,, and J. Schupbach. 1999. Reverse transcriptase assay based on product enhancement for assessing the drug susceptibility of retroviruses, p. 301–312. In D. Kinchington and, R. F. Schinazi (ed.), Antiviral Methods and Protocols, vol. 24. Humana Press, Inc., Totowa, NJ.
32. Boni, J.,, C. Shah,, M. Flepp,, R. Luthy, and, J. Schupbach. 2004b. Detection of low copy numbers of HIV-1 proviral DNA in patient PBMCs by a high-input, sequence-capture PCR (Mega-PCR). J. Med. Virol. 72: 1– 9.
33. Boni, R.,, A. Davis-Daneshfar,, G. Burg,, D. Fuchs, and, G. S. Wood. 1996b. No detection of HTLV-I proviral DNA in lesional skin biopsies from Swiss and German patients with cutaneous T-cell lymphoma. Br. J. Dermatol. 134: 282– 284.
34. Borg, A.,, J. A. Yin,, P. R. Johnson,, J. Tosswill,, M. Saunders, and, D. Morris. 1996. Successful treatment of HTLV-1-associated acute adult T-cell leukaemia lymphoma by allogeneic bone marrow transplantation. Br. J. Haematol. 94: 713– 715.
35. Borrow, P.,, H. Lewicki,, X. Wei,, M. S. Horwitz,, N. Peffer,, H. Meyers,, J. A. Nelson,, J. E. Gairin,, B. H. Hahn,, M. B. Oldstone, and, G. M. Shaw. 1997. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 3: 205– 211.
36. Branson, B. M.,, H. H. Handsfield,, M. A. Lampe,, R. S. Janssen,, A. W. Taylor,, S. B. Lyss, and, J. E. Clark. 2006. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recommend. Rep. 55: 1– 17; quiz, CE11–CE14.
37. Brenchley, J. M.,, T. W. Schacker,, L. E. Ruff,, D. A. Price,, J. H. Taylor,, G. J. Beilman,, P. L. Nguyen,, A. Khoruts,, M. Larson,, A. T. Haase, and, D. C. Douek. 2004. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 200: 749– 759.
38. Brinkhof, M. W.,, J. Boni,, F. Steiner,, Z. Tomasik,, D. Nadal, and, J. Schupbach. 2006. Evaluation of p24-based antiretroviral treatment monitoring in pediatric HIV-1 infection: prediction of the CD4+ T-cell changes between consecutive visits. J. Acquir. Immune Defic. Syndr. 41: 557– 562.
39. Burgard, M.,, M. J. Mayaux,, S. Blanche,, A. Ferroni,, M. L. Guihard-Moscato,, M. C. Allemon,, N. Ciraru-Vigneron,, G. Firtion,, C. Floch,, F. Guillot, et al. 1992. The use of viral culture and p24 antigen testing to diagnose human immunodeficiency virus infection in neonates. The HIV Infection in Newborns French Collaborative Study Group. N. Engl. J. Med. 327: 1192– 1197.
40. Bürgisser, P.,, P. Vernazza,, M. Flepp,, J. Böni,, Z. Tomasik,, U. Hummel,, G. Pantaleo,, J. Schüpbach, and the Swiss HIV Cohort Study. 2000. Performance of five different assays for the quantification of viral load in subjects infected with various subtypes of HIV-1. J. Acquir. Immune Defic. Syndr. 23: 138– 144.
41. Busch, M.,, G. Satten,, N. Sakahara,, P. Garrett, and, S. Herman. 1997. Time course and dynamics of viremia during early stages of HIV seroconversion, abstr. 203. 4th Conf. Retrovir. Oppor. Infect., Washington, DC, 22 to 26 January 1997.
42. Busch, M. P.,, L. L. Lee,, G. A. Satten,, D. R. Henrard,, H. Farzadegan,, K. E. Nelson,, S. Read,, R. Y. Dodd, and, L. R. Petersen. 1995. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion 35: 91– 97.
43. Busch, M. P.,, and G. A. Satten. 1997. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am. J. Med. 102: 117– 126.
44. Byrne, B. C.,, J. J. Li,, J. Sninsky, and, B. J. Poiesz. 1988. Detection of HIV-1 RNA sequences by in vitro DNA amplification. Nucleic Acids Res. 16: 4165.
45. Calattini, S.,, S. A. Chevalier,, R. Duprez,, P. Afonso,, A. Froment,, A. Gessain, and, R. Mahieux. 2006. Human T-cell lymphotropic virus type 3: complete nucleotide sequence and characterization of the human tax3 protein. J. Virol. 80: 9876– 9888.
46. Calattini, S.,, S. A. Chevalier,, R. Duprez,, S. Bassot,, A. Froment,, R. Mahieux, and, A. Gessain. 2005. Discovery of a new human T-cell lymphotropic virus (HTLV-3) in Central Africa. Retrovirology 2: 30.
47. Cameron, P. U.,, R. L. Dawkins,, J. A. Armstrong, and, E. Bonifacio. 1987. Western blot profiles, lymph node ultrastructure and viral expression in HIV-infected patients: a correlative study. Clin. Exp. Immunol. 68: 465– 478.
48. Cameron, P. U.,, A. J. Handley,, D. C. Baylis,, A. E. Solomon,, N. Bernard,, D. F. Purcell, and, S. R. Lewin. 2007. Preferential infection of dendritic cells during human immunodeficiency virus type 1 infection of blood leukocytes. J. Virol. 81: 2297– 2306.
49. Campo, J.,, M. A. Perea,, J. del Romero,, J. Cano,, V. Hernando, and, A. Bascones. 2006. Oral transmission of HIV, reality or fiction? An update. Oral Dis. 12: 219– 228.
50. Candotti, D.,, A. Richetin,, B. Cant,, J. Temple,, C. Sims,, I. Reeves,, J. A. Barbara, and, J. P. Allain. 2003. Evaluation of a transcription-mediated amplification-based HCV and HIV-1 RNA duplex assay for screening individual blood donations: a comparison with a minipool testing system. Transfusion 43: 215– 225.
51. Carrillo, A.,, K. D. Stewart,, H. L. Sham,, D. W. Norbeck,, W. E. Kohlbrenner,, J. M. Leonard,, D. J. Kempf, and, A. Molla. 1998. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J. Virol. 72: 7532– 7541.
52. Carvalho, E. M.,, and A. Da Fonseca Porto. 2004. Epidemiological and clinical interaction between HTLV-1 and Strongyloides stercoralis. Parasite Immunol. 26: 487– 497.
53. Caterino-de-Araujo, A.,, E. de los Santos-Fortuna,, M. C. Meleiro,, J. Suleiman,, M. L. Calabro,, A. Favero,, A. De Rossi, and, L. Chieco-Bianchi. 1998. Sensitivity of two enzyme-linked immunosorbent assay tests in relation to Western blot in detecting human T-cell lymphotropic virus types I and II infection among HIV-1 infected patients from Sao Paulo, Brazil. Diagn. Microbiol. Infect. Dis. 30: 173– 182.
54. Cavert, W.,, D. W. Notermans,, K. Staskus,, S. W. Wietgrefe,, M. Zupancic,, K. Gebhard,, K. Henry,, Z. Q. Zhang,, R. Mills,, H. McDade,, J. Goudsmit,, S. A. Danner, and, A. T. Haase. 1997. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 276: 960– 964.
55. Cavrois, M.,, I. Leclercq,, O. Gout,, A. Gessain,, S. Wain-Hobson, and, E. Wattel. 1998. Persistent oligoclonal expansion of human T-cell leukemia virus type 1-infected circulating cells in patients with tropical spastic paraparesis/HTLV-1 associated myelopathy. Oncogene 17: 77– 82.
56. Centers for Disease Control. 1989. Interpretation and use of the Western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. MMWR Morb. Mortal. Wkly. Rep. 38: 1– 7.
57. Centers for Disease Control. 1992. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb. Mortal. Wkly. Rep. 41: 1– 19.
58. Centers for Disease Control and Prevention. 1995. Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood–France, United Kingdom, and United States, January 1988-August 1994. MMWR Morb. Mortal. Wkly. Rep. 44: 929– 933.
59. Centers for Disease Control and Prevention and the USPHS Working Group. 1993. Guidelines for counselling persons infected with human T-lymphotropic virus type I (HTLV-I) and type II (HTLV-II). Ann. Intern. Med. 118: 448– 454.
60. Chakraborty, R.,, A. S. Morel,, J. K. Sutton,, V. Appay,, R. M. Ripley,, T. Dong,, T. Rostron,, S. Ogola,, T. Palakudy,, R. Musoke,, A. D’Agostino,, M. Ritter, and, S. L. Rowland-Jones. 2005. Correlates of delayed disease progression in HIV-1-infected Kenyan children. J. Immunol. 174: 8191– 8199.
61. Cheynier, R.,, S. Henrichwark,, F. Hadida,, E. Pelletier,, E. Oksenhendler,, B. Autran, and, S. Wain-Hobson. 1994. HIV and T cell expansion in splenic white pulps is accompanied by infiltration of HIV-specific cytotoxic T lymphocytes. Cell 78: 373– 387.
62. Chun, T. W.,, L. Carruth,, D. Finzi,, X. Shen,, J. A. DiGiuseppe,, H. Taylor,, M. Hermankova,, K. Chadwick,, J. Margolick,, T. C. Quinn,, Y. H. Kuo,, R. Brookmeyer,, M. A. Zeiger,, P. Barditch-Crovo, and, R. F. Siliciano. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387: 183– 188.
63. Chun, T. W.,, D. Engel,, M. M. Berrey,, T. Shea,, L. Corey, and, A. S. Fauci. 1998. Early Establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 95: 8869– 8873.
64. Clapham, P. R.,, and A. McKnight. 2002. Cell surface receptors, virus entry and tropism of primate lentiviruses. J. Gen. Virol. 83: 1809– 1829.
65. Clark, S. J.,, M. S. Saag,, W. D. Decker,, S. Campbell-Hill,, J. L. Roberson,, P. J. Veldkamp,, J. C. Kappes,, B. H. Hahn, and, G. M. Shaw. 1991. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N. Engl. J. Med. 324: 954– 960.
66. Clavel, F.,, D. Guetard,, F. Brun-Vezinet,, S. Chamaret,, M. A. Rey,, M. O. Santos-Ferreira,, A. G. Laurent,, C. Dauguet,, C. Katlama, and, C. Rouzioux. 1986a. Isolation of a new human retrovirus from West African patients with AIDS. Science 233: 343– 346.
67. Clavel, F.,, M. Guyader,, D. Guetard,, M. Salle,, L. Montagnier, and, M. Alizon. 1986b. Molecular cloning and polymorphism of the human immune deficiency virus type 2. Nature 324: 691– 695.
68. Clevenbergh, P.,, R. Garraffo,, J. Durant, and, P. Dellamonica. 2002. PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results. AIDS 16: 2311– 2315.
69. Cocchi, F.,, A. L. De Vico,, A. Garzino-Demo,, S. K. Arya,, R. C. Gallo, and, P. Lusso. 1995. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270: 1811– 1815.
70. Coffin, J. M. 1992. Genetic diversity and evolution of retroviruses. Curr. Top. Microbiol. Immunol. 176: 143– 164.
71. Collins, C. L.,, R. J. Mullan, and, R. R. Moseley. 1991. HIV safety guidelines and laboratory training. NIOSH. Public Health Rep. 106: 727– 732.
72. Connick, E.,, D. G. Marr,, X. Q. Zhang,, S. J. Clark,, M. S. Saag,, R. T. Schooley, and, T. J. Curiel. 1996. HIV-specific cellular and humoral immune responses in primary HIV infection. AIDS Res. Hum. Retrovir. 12: 1129– 1140.
73. Constantine, N. T.,, G. van der Groen,, E. M. Belsey, and, H. Tamashiro. 1994. Sensitivity of HIV-antibody assays determined by seroconversion panels. AIDS 8: 1715– 1720.
74. Coombs, R. W.,, S. L. Welles,, C. Hooper,, P. S. Reichelderfer,, R. T. D’Aquila,, A. J. Japour,, V. A. Johnson,, D. R. Kuritzkes,, D. D. Richman,, S. Kwok,, J. Todd,, J. B. Jackson,, V. DeGruttola,, C. S. Crumpacker, and, J. Kahn. 1996. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. J. Infect. Dis. 174: 704– 712.
75. Cornelissen, M.,, G. Mulder-Kampinga,, J. Veenstra,, F. Zorgdrager,, C. Kuiken,, S. Hartman,, J. Dekker,, L. van der Hoek,, C. Sol, and, R. Coutinho. 1995. Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing/SI phenotypically mixed human immunodeficiency virus population. J. Virol. 69: 1810– 1818.
76. Coste, J.,, B. Montes,, J. Reynes,, M. Peeters,, C. Segarra,, J. P. Vendrell,, E. Delaporte, and, M. Segondy. 1996. Comparative evaluation of three assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma. J. Med. Virol. 50: 293– 302.
78. Cunningham, C. K.,, T. T. Charbonneau,, K. Song,, D. Patterson,, T. Sullivan,, T. Cummins, and, B. Poiesz. 1999. Comparison of human immunodeficiency virus 1 DNA polymerase chain reaction and qualitative and quantitative RNA polymerase chain reaction in human immunodeficiency virus 1-exposed infants. Pediatr. Infect. Dis. 18: 30– 35.
79. Daar, E. S.,, T. Moudgil,, R. D. Meyer, and, D. D. Ho. 1991. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N. Engl. J. Med. 324: 961– 964.
80. Daenke, S.,, S. Nightingale,, J. K. Cruickshank, and, C. R. Bangham. 1990. Sequence variants of human T-cell lymphotropic virus type I from patients with tropical spastic paraparesis and adult T-cell leukemia do not distinguish neurological from leukemic isolates. J. Virol. 64: 1278– 1282.
81. Davidson, F.,, C. Lycett,, L. M. Jarvis,, D. Kerr,, S. Lumley,, J. Petrik, and, B. C. Dow. 2006. Detection of HTLV-I and -II in Scottish blood donor samples and archive donations. Vox Sang. 91: 231– 236.
82. Debyser, Z.,, E. Vanwijngaerden,, K. Vanlaethem,, K. Beuselinck,, M. Reynders,, E. Declercq,, J. Desmyter, and, A. M. Vandamme. 1998. Failure to quantify viral load with two of the three commercial methods in a pregnant woman harboring an HIV type 1 subtype G strain. AIDS Res. Hum. Retrovir. 14: 453– 459.
83. De Castro-Costa, C. M.,, A. Q. Araujo,, M. M. Barreto,, O. M. Takayanagui,, M. P. Sohler,, E. L. da Silva,, S. M. de Paula,, R. Ishak,, J. G. Ribas,, L. C. Rovirosa,, H. Carton,, E. Gotuzzo,, W. W. Hall,, S. Montano,, E. L. Murphy,, J. Oger,, C. Remondegui, and, G. P. Taylor. 2006. Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM). AIDS Res. Hum. Retrovir. 22: 931– 935.
84. Deeks, S. G.,, N. S. Hellmann,, R. M. Grant,, N. T. Parkin,, C. J. Petropoulos,, M. Becker,, W. Symonds,, M. Chesney, and, P. A. Volberding. 1999. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J. Infect. Dis. 179: 1375– 1381.
85. Defer, C.,, J. Coste,, F. Descamps,, S. Voisin,, J. M. Lemaire,, M. Maniez, and, A. M. Couroucé. 1995. Contribution of polymerase chain reaction and radioimmunoprecipitation assay in the confirmation of human T-lymphotropic virus infection in French blood donors. Retrovirus Study Group of the French Society of Blood Transfusion. Transfusion 35: 596– 600.
86. Delaney, K. P.,, B. M. Branson,, A. Uniyal,, P. R. Kerndt,, P. A. Keenan,, K. Jafa,, A. D. Gardner,, D. J. Jamieson, and, M. Bulterys. 2006. Performance of an oral fluid rapid HIV-1/2 test: experience from four CDC studies. AIDS 20: 1655– 1660.
87. De Leys, R.,, B. Vanderborght,, M. Vanden Haesevelde,, L. Heyndrickx,, A. van Geel,, C. Wauters,, R. Bernaerts,, E. Saman,, P. Nijs, and, B. Willems. 1990. Isolation and partial characterization of an unusual human immunodeficiency retrovirus from two persons of west-central African origin. J. Virol. 64: 1207– 1216.
88. DeLuca, C.,, H. Kwon,, R. Lin,, M. Wainberg, and, J. Hiscott. 1999. NF-kappaB activation and HIV-1 induced apoptosis. Cytokine Growth Factor Rev. 10: 235– 253.
89. Delwart, E. L.,, H. W. Sheppard,, B. D. Walker,, J. Goudsmit, and, J. I. Mullins. 1994. Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J. Virol. 68: 6672– 6683.
90. Descamps, D.,, M. L. Chaix,, P. Andre,, V. Brodard,, J. Cottalorda,, C. Deveau,, M. Harzic,, D. Ingrand,, J. Izopet,, E. Kohli,, B. Masquelier,, S. Mouajjah,, P. Palmer,, I. Pellegrin,, J. C. Plantier,, C. Poggi,, S. Rogez,, A. Ruffault,, V. Schneider,, A. Signori-Schmuck,, C. Tamalet,, M. Wirden,, C. Rouzioux,, F. Brun-Vezinet,, L. Meyer, and, D. Costagliola. 2005. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001–2002. J. Acquir. Immune Defic. Syndr. 38: 545– 552.
91. Divine, B. T.,, S. M. Greby,, K. V. Hunt,, M. L. Kamb,, R. W. Steketee, and, L. Warner. 2001. Revised guidelines for HIV counseling, testing, and referral. MMWR Recommend. Rep. 50 (RR-19) : 1– 58.
92. Dong, B.,, S. Kim,, S. Hong,, J. Das Gupta,, K. Malathi,, E. A. Klein,, D. Ganem,, J. L. Derisi,, S. A. Chow, and, R. H. Silverman. 2007. An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc. Natl. Acad. Sci. USA 104: 1655– 1660.
93. Douceron, H.,, L. Deforges,, R. Gherardi,, A. Sobel, and, P. Chariot. 1993. Long-lasting postmortem viability of human immunodeficiency virus: a potential risk in forensic medicine practice. Forensic Sci. Int. 60: 61– 66.
94. Downs, A. M.,, G. Salamina, and, R. A. Ancelle-Park. 1995. Incubation period of vertically acquired AIDS in Europe before widespread use of prophylactic therapies. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 9: 297– 304.
95. Drosten, C.,, M. Panning,, J. F. Drexler,, F. Hansel,, C. Pedroso,, J. Yeats,, L. K. de Souza Luna,, M. Samuel,, B. Liedigk,, U. Lippert,, M. Sturmer,, H. W. Doerr,, C. Brites, and, W. Preiser. 2006. Ultrasensitive monitoring of HIV-1 viral load by a low-cost real-time reverse transcription-PCR assay with internal control for the 5′ long terminal repeat domain. Clin. Chem. 52: 1258– 1266.
96. Eiraku, N.,, P. Novoa,, M. da Costa Ferreira,, C. Monken,, R. Ishak,, O. da Costa Ferreira,, S. W. Zhu,, R. Lorenco,, M. Ishak,, V. Azvedo,, J. Guerreiro,, M. P. de Oliveira,, P. Loureiro,, N. Hammerschlak,, S. Ijichi, and, W. M. Hall. 1996. Identification and characterization of a new and distinct molecular subtype of human T-cell lymphotropic virus type 2. J. Virol. 70: 1481– 1492.
97. Embretson, J.,, M. Zupancic,, J. L. Ribas,, A. Burke,, P. Racz,, K. Tenner-Racz, and, A. T. Haase. 1993. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362: 359– 362.
98. Ena, J.,, R. F. Ruiz de Apodaca,, C. Amador,, C. Benito, and, F. Pasquau. 2006. Net benefits of resistance testing directed therapy compared with standard of care in HIV-infected patients with virological failure: a meta-analysis. Enferm. Infecc. Microbiol. Clin. 24: 232– 237.
99. Etoh, K.,, S. Tamiya,, K. Yamaguchi,, A. Okayama,, H. Tsubouchi,, T. Ideta,, N. Mueller,, K. Takatsuki, and, M. Matsuoka. 1997. Persistent clonal proliferation of human T-lymphotropic virus type I-infected cells in vivo. Cancer Res. 57: 4862– 4867.
100. Etoh, K.,, K. Yamaguchi,, S. Tokudome,, T. Watanabe,, A. Okayama,, S. Stuver,, N. Mueller,, K. Takatsuki, and, M. Matsuoka. 1999. Rapid quantification of HTLV-I provirus load: detection of monoclonal proliferation of HTLV-I-infected cells among blood donors. Int. J. Cancer 81: 859– 864.
101. Fan, H. 2007. A new human retrovirus associated with prostate cancer. Proc. Natl. Acad. Sci. USA 104: 1449– 1450.
102. Farias de Carvalho, S. M.,, M. S. Pombo de Oliveira,, L. C. Thuler,, M. Rios,, R. C. Coelho,, L. C. Rubim,, E. M. Silva,, A. M. Reis, and, D. Catovsky. 1997. HTLV-I and HTLV-II infections in hematologic disorder patients, cancer patients, and healthy individuals from Rio de Janeiro, Brazil. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 15: 238– 242.
103. Fauci, A. S. 1993. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 262: 1011– 1018.
104. Feller, A. C.,, and J. Diebold. 2004. Histopathology of Nodal and Extranodal Non-Hodgkin’s Lymphomas (Based on the WHO Classification), 3rd ed., p. 131. Springer Verlag, Berlin, Germany.
105. Feuer, G.,, and P. L. Green. 2005. Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2. Oncogene 24: 5996– 6004.
106. Fiebig, E. W.,, D. J. Wright,, B. D. Rawal,, P. E. Garrett,, R. T. Schumacher,, L. Peddada,, C. Heldebrant,, R. Smith,, A. Conrad,, S. H. Kleinman, and, M. P. Busch. 2003. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17: 1871– 1879.
107. Finzi, D.,, J. Blankson,, J. D. Siliciano,, J. B. Margolick,, K. Chadwick,, T. Pierson,, K. Smith,, J. Lisziewicz,, F. Lori,, C. Flexner,, T. C. Quinn,, R. E. Chaisson,, E. Rosenberg,, B. Walker,, S. Gange,, J. Gallant, and, R. F. Siliciano. 1999. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5: 512– 517.
108. Finzi, D.,, M. Hermankova,, T. Pierson,, L. M. Carruth,, C. Buck,, R. E. Chaisson,, T. C. Quinn,, K. Chadwick,, J. Margolick,, R. Brookmeyer,, J. Gallant,, M. Markowitz,, D. D. Ho,, D. D. Richman, and, R. F. Siliciano. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 1295– 1300.
109. Fischer, M.,, R. Hafner,, C. Schneider,, A. Trkola,, B. Joos,, H. Joller,, B. Hirschel,, R. Weber, and, H. F. Gunthard. 2003. HIV RNA in plasma rebounds within days during structured treatment interruptions. AIDS 17: 195– 199.
110. Fiscus, S. A.,, B. Cheng,, S. M. Crowe,, L. Demeter,, C. Jennings,, V. Miller,, R. Respess, and, W. Stevens. 2006. HIV-1 viral load assays for resource-limited settings. PLoS Med. 3: e417.
111. Franchini, G.,, R. Fukumoto, and, J. R. Fullen. 2003. T-cell control by human T-cell leukemia/lymphoma virus type 1. Int. J. Hematol. 78: 280– 296.
112. Fukushima, T.,, Y. Miyazaki,, S. Honda,, F. Kawano,, Y. Moriuchi,, M. Masuda,, R. Tanosaki,, A. Utsunomiya,, N. Uike,, S. Yoshida,, J. Okamura, and, M. Tomonaga. 2005. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia 19: 829– 834.
113. Furtado, M. R.,, D. S. Callaway,, J. P. Phair,, K. J. Kunstman,, J. L. Stanton,, C. A. Macken,, A. S. Perelson, and, S. M. Wolinsky. 1999. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N. Engl. J. Med. 340: 1614– 1622.
114. Gabet, A. S.,, F. Mortreux,, A. Talarmin,, Y. Plumelle,, I. Leclercq,, A. Leroy,, A. Gessain,, E. Clity,, M. Joubert, and, E. Wattel. 2000. High circulating proviral load with oligoclonal expansion of HTLV-1 bearing T cells in HTLV-1 carriers with strongyloidiasis. Oncogene 19: 4954– 4960.
115. Galli, R.,, L. Merrick,, M. Friesenhahn, and, R. Ziermann. 2005. Comprehensive comparison of the Versant HIV-1 RNA 3.0 (bDNA) and Cobas Amplicor HIV-1 Monitor 1.5 assays on 1,000 clinical specimens. J. Clin. Virol. 34: 245– 252.
116. Gallo, R. C.,, S. Z. Salahuddin,, M. Popovic,, G. M. Shearer,, M. Kaplan,, B. F. Haynes,, T. J. Palker,, R. Redfield,, J. Oleske,, B. Safai, et al. 1984. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224: 500– 503.
117. Gao, F.,, E. Bailes,, D. L. Robertson,, Y. L. Chen,, C. M. Rodenburg,, S. F. Michael,, L. B. Cummins,, L. O. Arthur,, M. Peeters,, G. M. Shaw,, P. M. Sharp, and, B. H. Hahn. 1999. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397: 436– 441.
118. Garcia-Bujalance, S.,, C. L. de Guevara,, J. Gonzalez-Garcia,, J. R. Arribas, and, A. Gutierrez. 2005. Comparison between sequence analysis and a line probe assay for testing genotypic resistance of human immunodeficiency virus type 1 to antiretroviral drugs. J. Clin. Microbiol. 43: 4186– 4188.
119. Geijtenbeek, T. B.,, and Y. van Kooyk. 2003. DC-SIGN: a novel HIV receptor on DCs that mediates HIV-1 transmission. Curr. Top. Microbiol. Immunol. 276: 31– 54.
120. Gessain, A. 1996. Virological aspects of tropical spastic paraparesis/HTLV-I associated myelopathy and HTLV-I infection. J. Neurovirol. 2: 299– 306.
121. Gessain, A.,, F. Barin,, J. C. Vernant,, O. Gout,, L. Maurs,, A. Calender, and, G. de The. 1985. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet ii: 407– 410.
122. Gessain, A.,, and G. de The. 1996. Geographic and molecular epidemiology of primate T lymphotropic retroviruses: HTLV-I, HTLV-II, STLV-I, STLV-PP, and PTLV-L. Adv. Virus Res. 47: 377– 426.
123. Gessain, A.,, A. Louie,, O. Gout,, R. C. Gallo, and, G. Franchini. 1991. Human T-cell leukemia-lymphoma virus type I (HTLV-I) expression in fresh peripheral blood mononuclear cells from patients with tropical spastic paraparesis/HTLV-I-associated myelopathy. J. Virol. 65: 1628– 1633.
124. Giles, R. E.,, K. R. Perry, and, J. V. Parry. 1999. Simple/rapid test devices for anti-HIV screening: do they come up to the mark? J. Med. Virol. 59: 104– 109.
125. Ginocchio, C. C.,, X. P. Wang,, M. H. Kaplan,, G. Mulligan,, D. Witt,, J. W. Romano,, M. Cronin, and, R. Carroll. 1997. Effects of specimen collection, processing, and storage conditions on stability of human immunodeficiency virus type 1 RNA levels in plasma. J. Clin. Microbiol. 35: 2886– 2893.
126. Gottesman, B. S.,, Z. Grossman,, M. Lorber,, I. Levi,, P. Shitrit,, M. Katzir,, E. Shahar,, G. Gottesman, and, M. Chowers. 2006. Comparative performance of the Amplicor HIV-1 Monitor assay versus NucliSens EasyQ in HIV subtype C-infected patients. J. Med. Virol. 78: 883– 887.
127. Gottlieb, M. S.,, R. Schroff,, H. M. Schanker,, J. D. Weisman,, P. T. Fan,, R. A. Wolf, and, A. Saxon. 1981. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N. Engl. J. Med. 305: 1425– 1431.
128. Granade, T. C.,, S. K. Phillips,, B. Parekh,, P. Gomez,, W. Kitson-Piggott,, H. Oleander,, B. Mahabir,, W. Charles, and, S. Lee-Thomas. 1998. Detection of antibodies to human immunodeficiency virus type 1 in oral fluids: a large-scale evaluation of immunoassay performance. Clin. Diagn. Lab. Immunol. 5: 171– 175.
129. Grassmann, R.,, M. Aboud, and, K. T. Jeang. 2005. Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene 24: 5976– 5985.
130. Graziosi, C.,, G. Pantaleo,, L. Butini,, J. F. Demarest,, M. S. Saag,, G. M. Shaw, and, A. S. Fauci. 1993. Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 90: 6405– 6409.
131. Griffiths, D. J.,, C. Voisset,, P. J. Venables, and, R. A. Weiss. 2002. Novel endogenous retrovirus in rabbits previously reported as human retrovirus 5. J. Virol. 76: 7094– 7102.
132. Grindstaff, P.,, and G. Gruener. 2005. The peripheral nervous system complications of HTLV-1 myelopathy (HAM/TSP) syndromes. Semin. Neurol. 25: 315– 327.
133. Guadalupe, M.,, S. Sankaran,, M. D. George,, E. Reay,, D. Verhoeven,, B. L. Shacklett,, J. Flamm,, J. Wegelin,, T. Prindiville, and, S. Dandekar. 2006. Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J. Virol. 80: 8236– 8247.
134. Guan, M. 2007. Frequency, causes and new challenges of indeterminate results in Western blot confirmatory testing for antibodies to human immunodeficiency virus. Clin. Vaccine Immunol. 14: 649– 659.
135. Gueudin, M.,, J. C. Plantier,, V. Lemee,, M. P. Schmitt,, L. Chartier,, T. Bourlet,, A. Ruffault,, F. Damond,, M. Vray, and, F. Simon. 2007. Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes. J. Acquir. Immune Defic. Syndr. 44: 500– 505.
136. Gurtler, L.,, A. Muhlbacher,, U. Michl,, H. Hofmann,, G. G. Paggi,, V. Bossi,, R. Thorstensson,, R. G. Villaescusa,, A. Eiras,, J. M. Hernandez,, W. Melchior,, F. Donie, and, B. Weber. 1998. Reduction of the diagnostic window with a new combined p24 antigen and human immunodeficiency virus antibody screening assay. J. Virol. Methods 75: 27– 38.
137. Gurtler, L. G.,, P. H. Hauser,, J. Eberle,, A. von Brunn,, S. Knapp,, L. Zekeng,, J. M. Tsague, and, L. Kaptue. 1994. A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon. J. Virol. 68: 1581– 1585.
138. Hall, W. W.,, and M. Fujii. 2005. Deregulation of cell-signaling pathways in HTLV-1 infection. Oncogene 24: 5965– 5975.
139. Hall, W. W.,, H. Takahashi,, C. Liu,, M. H. Kaplan,, O. Scheewind,, S. Ijichi,, K. Nagashima, and, R. C. Gallo. 1992. Multiple isolates and characteristics of human T-cell leukemia virus type II. J. Virol. 66: 2456– 2463.
140. Healey, D. S.,, and W. V. Bolton. 1993. Apparent HIV-1 glycoprotein reactivity on Western blot in uninfected blood donors. AIDS 7: 655– 658.
141. Heath, S. L.,, J. G. Tew,, J. G. Tew,, A. K. Szakal, and, G. F. Burton. 1995. Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 377: 740– 744.
142. Hemelaar, J.,, E. Gouws,, P. D. Ghys, and, S. Osmanov. 2006. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20: W13– W23.
143. Heneine, W.,, S. Yamamoto,, W. M. Switzer,, T. J. Spira, and, T. M. Folks. 1995. Detection of reverse transcriptase by a highly sensitive assay in sera from persons infected with human immunodeficiency virus type 1. J. Infect. Dis. 171: 1210– 1216.
144. Henrard, D. R.,, J. F. Phillips,, L. R. Muenz,, W. A. Blattner,, D. Wiesner,, M. E. Eyster, and, J. J. Goedert. 1995. Natural history of HIV-1 cell-free viremia. JAMA 274: 554– 558.
145. Heraud, J. M.,, F. Mortreux,, F. Merien,, H. Contamin,, R. Mahieux,, J. F. Pouliquen,, E. Wattel,, A. Gessain,, H. de The,, A. Bazarbachi,, O. Hermine, and, M. Kazanji. 2006. The efficacy of combined therapy of arsenic trioxide and alpha interferon in human T-cell leukemia virus type-1-infected squirrel monkeys ( Saimiri sciureus). Antivir. Res. 70: 132– 139.
146. Herzberg, M. C.,, A. Weinberg, and, S. M. Wahl. 2006. (C3) The oral epithelial cell and first encounters with HIV-1. Adv. Dent. Res. 19: 158– 166.
147. Hino, S.,, S. Katamine,, H. Miyata,, Y. Tsuji,, T. Yamabe, and, T. Miyamoto. 1996. Primary prevention of HTLV-I in Japan. J. Acquir. Immune Defic. Syndr. Human Retrovirol. 13: S199– S203.
148. Hirata, M.,, J. Hayashi,, A. Noguchi,, K. Nakashima,, W. Kajiyama,, S. Kashiwagi, and, T. Sawada. 1992. The effects of breastfeeding and presence of antibody to p40tax protein of human T cell lymphotropic virus type-I on mother to child transmission. Int. J. Epidemiol. 21: 989– 994.
149. Hirsch, M. S.,, F. Brun-Vezinet,, B. Clotet,, B. Conway,, D. R. Kuritzkes,, R. T. D’Aquila,, L. M. Demeter,, S. M. Hammer,, V. A. Johnson,, C. Loveday,, J. W. Mellors,, D. M. Jacobsen, and, D. D. Richman. 2003. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin. Infect. Dis. 37: 113– 128.
150. Hisada, M.,, W. J. Miley, and, R. J. Biggar. 2005. Provirus load is lower in human T lymphotropic virus (HTLV)-II carriers than in HTLV-I carriers: a key difference in viral pathogenesis? J. Infect. Dis. 191: 1383– 1386.
151. Hisada, M.,, A. Okayama,, N. Tachibana,, S. O. Stuver,, D. L. Spiegelman,, H. Tsubouchi, and, N. E. Mueller. 1998. Predictors of level of circulating abnormal lymphocytes among human T-lymphotropic virus type I carriers in Japan. Int. J. Cancer 77: 188– 192.
152. Hjelle, B.,, R. Mills,, S. Swenson,, G. Mertz,, C. Key, and, S. Allen. 1991. Incidence of hairy cell leukemia, mycosis fungoides, and chronic lymphocytic leukemia in first known HTLV-II-endemic population. J. Infect. Dis. 163: 435– 440.
153. Ho, D. D.,, T. Moudgil, and, M. Alam. 1989. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N. Engl. J. Med. 321: 1621– 1625.
154. Hunt, P. W. 2007. Role of immune activation in HIV pathogenesis. Curr. HIV/AIDS Rep. 4: 42– 47.
155. Igakura, T.,, J. C. Stinchcombe,, P. K. Goon,, G. P. Taylor,, J. N. Weber,, G. M. Griffiths,, Y. Tanaka,, M. Osame, and, C. R. Bangham. 2003. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science 299: 1713– 1716.
156. Igarashi, T.,, C. R. Brown,, Y. Endo,, A. Buckler-White,, R. Plishka,, N. Bischofberger,, V. Hirsch, and, M. A. Martin. 2001. Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): implications for HIV-1 infections of humans. Proc. Natl. Acad. Sci. USA 98: 658– 663.
157. Ijichi, S.,, M. B. Ramundo,, H. Takahashi, and, W. W. Hall. 1992. In vivo cellular tropism of human T cell leukemia virus type II (HTLV-II). J. Exp. Med. 176: 293– 296.
158. Iwakura, Y.,, S. Saijo,, Y. Kioka,, J. Nakayama-Yamada,, K. Itagaki,, M. Tosu,, M. Asano,, Y. Kanai, and, K. Kakimoto. 1995. Autoimmunity induction by human T cell leukemia virus type 1 in transgenic mice that develop chronic inflammatory arthropathy resembling rheumatoid arthritis in humans. J. Immunol. 155: 1588– 1598.
159. Iwasaki, Y. 1993. Human T cell leukemia virus type I infection and chronic myelopathy. Brain Pathol. 3: 1– 10.
160. Jacobson, S. 2002. Immunopathogenesis of human T cell lymphotropic virus type I-associated neurologic disease. J. Infect. Dis. 186 (Suppl. 2) : S187– S192.
161. Jacobson, S.,, T. Lehky,, M. Nishimura,, S. Robinson,, D. E. McFarlin, and, S. Dhib-Jalbut. 1993. Isolation of HTLV-II from a patient with chronic, progressive neurological disease clinically indistinguishable from HTLV-I-associated myelopathy/tropical spastic paraparesis. Ann. Neurol. 33: 392– 396.
162. Jacobson, S.,, H. Shida,, D. E. McFarlin,, A. S. Fauci, and, S. Koenig. 1990. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature 348: 245– 248.
163. Jaffar, S.,, A. D. Grant,, J. Whitworth,, P. G. Smith, and, H. Whittle. 2004. The natural history of HIV-1 and HIV-2 infections in adults in Africa: a literature review. Bull. W. H. O. 82: 462– 469.
164. Jarvis, G. A.,, E. N. Janoff,, H. Cheng,, D. Devita,, C. Fasching,, C. E. McCulloch, and, E. L. Murphy. 2005. Human T lymphotropic virus type II infection and humoral responses to pneumococcal polysaccharide and tetanus toxoid vaccines. J. Infect. Dis. 191: 1239– 1244.
165. Jeang, K. T.,, C. Z. Giam,, F. Majone, and, M. Aboud. 2004. Life, death, and tax: role of HTLV-I oncoprotein in genetic instability and cellular transformation. J. Biol. Chem. 279: 31991– 31994.
166. Jetzt, A. E.,, H. Yu,, G. J. Klarmann,, Y. Ron,, B. D. Preston, and, J. P. Dougherty. 2000. High rate of recombination throughout the human immunodeficiency virus type 1 genome. J. Virol. 74: 1234– 1240.
167. Jin, X.,, D. E. Bauer,, S. E. Tuttleton,, S. Lewin,, A. Gettie,, J. Blanchard,, C. E. Irwin,, J. T. Safrit,, J. Mittler,, L. Weinberger,, L. G. Kostrikis,, L. Q. Zhang,, A. S. Perelson, and, D. D. Ho. 1999. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189: 991– 998.
168. Johnson, R. P.,, and A. Kaur. 2005. HIV: viral blitzkrieg. Nature 434: 1080– 1081.
169. Johnson, V. A.,, F. Brun-Vezinet,, B. Clotet,, D. R. Kuritzkes,, D. Pillay,, J. M. Schapiro, and, D. D. Richman. 2006. Update of the drug resistance mutations in HIV-1: Fall 2006. HIV Med. 14: 125– 130.
170. Jurriaans, S.,, B. Van Gemen,, G. J. Weverling,, D. Van Strijp,, P. Nara,, R. Coutinho,, M. Koot,, H. Schuitemaker, and, J. Goudsmit. 1994. The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology 204: 223– 233.
171. Kalyanaraman, V. S.,, M. G. Sarngadharan,, M. Robert-Guroff,, I. Miyoshi,, D. Golde, and, R. C. Gallo. 1982. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science 218: 571– 573.
172. Kannagi, M.,, S. Harada,, I. Maruyama,, H. Inoko,, H. Igarashi,, G. Kuwashima,, S. Sato,, M. Morita,, M. Kidokoro,, M. Sugimoto, et al. 1991. Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-I-infected cells. Int. Immunol. 3: 761– 767.
173. Karlic, H.,, M. Mostl,, H. Mucke,, B. Pavlova,, M. Pfeilstocker, and, R. Heinz. 1997. Association of human T-cell leukemia virus and myelodysplastic syndrome in a central European population. Cancer Res. 57: 4718– 4721.
174. Kashanchi, F.,, and J. N. Brady. 2005. Transcriptional and post-transcriptional gene regulation of HTLV-1. Oncogene 24: 5938– 5951.
175. Katsoulidou, A.,, M. Petrodaskalaki,, V. Sypsa,, E. Papachristou,, C. G. Anastassopoulou,, P. Gargalianos,, A. Karafoulidou,, M. Lazanas,, T. Kordossis,, A. Andoniadou, and, A. Hatzakis. 2006. Evaluation of the clinical sensitivity for the quantification of human immunodeficiency virus type 1 RNA in plasma: comparison of the new COBAS TaqMan HIV-1 with three current HIV-RNA assays–LCx HIV RNA quantitative, VERSANT HIV-1 RNA 3.0 (bDNA) and COBAS AMPLICOR HIV-1 Monitor v1.5. J. Virol. Methods 131: 168– 174.
176. Kaufmann, G. R.,, P. Cunningham,, A. D. Kelleher,, J. Zaunders,, A. Carr,, J. Vizzard,, M. Law, and, D. A. Cooper. 1998. Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group. J. Infect. Dis. 178: 1812– 1815.
177. Kaul, R.,, C. Pettengell,, P. M. Sheth,, S. Sunderji,, A. Biringer,, K. Macdonald,, S. Walmsley, and, A. Rebbapragada. 2008. The genital tract immune milieu: an important determinant of HIV susceptibility and secondary transmission. J. Reprod. Immunol. 77: 32– 40.
179. Kawano, F.,, K. Yamaguchi,, H. Nishimura,, H. Tsuda, and, K. Takatsuki. 1985. Variation in the clinical courses of adult T-cell leukemia. Cancer 55: 851– 856.
180. Kawano, N.,, K. Shimoda,, F. Ishikawa,, A. Taketomi,, T. Yoshizumi,, S. Shimoda,, S. Yoshida,, K. Uozumi,, S. Suzuki,, Y. Maehara, and, M. Harada. 2006. Adult T-cell leukemia development from a human T-cell leukemia virus type I carrier after a living-donor liver transplantation. Transplantation 82: 840– 843.
181. Kchour, G.,, N. J. Makhoul,, M. Mahmoudi,, M. M. Kooshyar,, A. Shirdel,, M. Rastin,, H. Rafatpanah,, M. Tarhini,, P. A. Zalloua,, O. Hermine,, R. Farid, and, A. Bazarbachi. 2007. Zidovudine and interferon-alpha treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran. Leuk. Lymphoma 48: 330– 336.
182. Keele, B. F.,, F. Van Heuverswyn,, Y. Li,, E. Bailes,, J. Takehisa,, M. L. Santiago,, F. Bibollet-Ruche,, Y. Chen,, L. V. Wain,, F. Liegeois,, S. Loul,, E. M. Ngole,, Y. Bienvenue,, E. Delaporte,, J. F. Brookfield,, P. M. Sharp,, G. M. Shaw,, M. Peeters, and, B. H. Hahn. 2006. Chimpanzee reservoirs of pandemic and non-pandemic HIV-1. Science 313: 523– 526.
183. Kehn, K.,, R. Berro,, C. de la Fuente,, K. Strouss,, E. Ghedin,, S. Dadgar,, M. E. Bottazzi,, A. Pumfery, and, F. Kashanchi. 2004. Mechanisms of HTLV-1 transformation. Front. Biosci. 9: 2347– 2372.
184. Kelen, G. D.,, J. B. Shahan, and, T. C. Quinn. 1999. Emergency department-based HIV screening and counseling: experience with rapid and standard serologic testing. Ann. Emerg. Med. 33: 147– 155.
185. Ketema, F.,, C. Zeh,, D. C. Edelman,, R. Saville, and, N. T. Constantine. 2001. Assessment of the performance of a rapid, lateral flow assay for the detection of antibodies to HIV. J. Acquir. Immune Defic. Syndr. 27: 63– 70.
186. Khabbaz, R. F.,, W. Heneine,, J. R. George,, B. Parekh,, T. Rowe,, T. Woods,, W. M. Switzer,, H. M. McClure,, M. Murphey-Corb, and, T. M. Folks. 1994. Brief report: infection of a laboratory worker with simian immunodeficiency virus. N. Engl. J. Med. 330: 172– 177.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.